HER2富集亚型预测早期HER2阳性乳腺癌曲妥珠单抗联合拉帕替尼无化疗后病理完全缓解(PAMELA):开放标签、单组、多中心2期试验
PAMELA是一项在西班牙19家医院开展的开放标签、单组2期试验,纳入151例既往未治疗的HER2阳性早期乳腺癌患者,给予拉帕替尼联合曲妥珠单抗治疗18周(激素受体阳性者加内分泌治疗),旨在验证HER2富集亚型患者从双重HER2阻断中获益最大的假设。结果显示,HER2富集亚型患者病理完全缓解率为41%,非HER2富集亚型为10%,比值比6.2(95%CI 2.3-16.8;P=0.0004)。
要点
- HER2富集亚型占基线患者的67%(101/151),是最常见的内在亚型。
- HER2富集亚型患者病理完全缓解率为41%(41/101),非HER2富集亚型为10%(5/50)。
- 比值比6.2(95%CI 2.3-16.8;P=0.0004),HER2富集亚型可识别可能从双重HER2阻断中获益的患者。
核心结论
- HER2富集亚型可识别可能从双重HER2阻断治疗中获益的HER2阳性乳腺癌患者。
研究设计与样本
- PAMELA为开放标签、单组、2期试验,在西班牙19家医院开展。
- 纳入151例年龄≥18岁、既往未治疗、中心确认HER2阳性、I-IIIA期浸润性乳腺癌女性患者,无论激素受体状态。
- 患者接受拉帕替尼(每日口服1000 mg)和曲妥珠单抗(负荷剂量8 mg/kg,后续6 mg/kg每3周静脉给药)治疗18周;激素受体阳性患者加用来曲唑(每日口服2.5 mg,若绝经后)或他莫昔芬(每日口服20 mg,若绝经前)。
- 末次研究治疗给药后1-3周进行手术;基线(第0天)和第14天肿瘤活检样本采用PAM50预测器确定内在分子亚型。
- 主要结局为HER2富集亚型预测手术时病理完全缓解的能力,在可评估人群(即有初始肿瘤活检样本并接受根治性手术的所有患者)中评估;安全性在所有接受至少一部分研究治疗的患者中评估。
主要发现
- 2013年10月28日至2015年11月26日,共招募151例患者,其中14例(9%)中止治疗,137例(91%)按计划完成治疗。
- 基线时,大多数患者为HER2富集亚型(101例[67%]),其次为luminal A(22例[15%])、luminal B(16例[11%])、基底样(9例[6%])和正常样(3例[2%])亚型。
- 手术时,151例患者中46例(30%,95%CI 23-39)在乳腺达到病理完全缓解。
- HER2富集亚型患者中41/101例(41%,95%CI 31-51)达到病理完全缓解,非HER2富集亚型患者中5/50例(10%,95%CI 4-23)达到病理完全缓解(比值比6.2,95%CI 2.3-16.8;P=0.0004)。
关键数值与推荐
- HER2富集亚型患者病理完全缓解率为41%(41/101,95%CI 31-51),非HER2富集亚型患者为10%(5/50,95%CI 4-23)。
- 比值比6.2(95%CI 2.3-16.8;P=0.0004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HER2-positive breast cancer consists of four intrinsic molecular subtypes-luminal A, luminal B, HER2-enriched, and basal-like-and a normal-like subtype, with the HER2-enriched subtype having the highest activation of the EGFR-HER2 pathway. We aimed to test the hypothesis that patients with the HER2-enriched subtype benefit the most from dual HER2 blockade. METHODS: PAMELA is an open-label, single-group, phase 2 trial done in 19 hospitals in Spain. We recruited female patients aged at least 18 years with previously untreated, centrally confirmed HER2-positive, stage I-IIIA invasive breast cancer regardless of hormone receptor status. Patients were given lapatinib (1000 mg per day orally) and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks intravenously) for 18 weeks; hormone receptor-positive patients were additionally given letrozole (2·5 mg per day orally; if menopausal) or tamoxifen (20 mg per day orally; if premenopausal). Surgery was done 1-3 weeks after the last dose of study treatment. Intrinsic molecular subtypes of tumour biopsy samples taken at baseline (day 0) and day 14 were determined with the PAM50 predictor. The primary outcome was the ability of the HER2-enriched subtype to predict pathological complete response at the time of surgery. The primary outcome was assessed in the evaluable population (ie, all patients who had initial tumour biopsy samples available and who underwent definitive surgery) and safety was assessed in all patients who received at least one part of study treatment. This study is registered with ClinicalTrials.gov, number NCT01973660, and is completed. FINDINGS: Between Oct 28, 2013, and Nov 26, 2015, we recruited 151 patients, of whom 14 (9%) discontinued treatment and 137 (91%) completed treatment as planned. At baseline, most patients had the HER2-enriched subtype (101 [67%]), followed by luminal A (22 [15%]), luminal B (16 [11%]), basal-like (nine [6%]), and normal-like (three [2%]) subtypes. At the time of surgery, 46 (30%, 95% CI 23-39) of 151 patients had pathological complete response in the breast. 41 (41%, 31-51) of 101 patients with the HER2-enriched subtype and five (10%, 4-23) of 50 patients with non-HER2-enriched subtypes achieved pathological complete response at the time of surgery (odds ratio 6·2, 95% CI 2·3-16·8; p=0·0004). INTERPRETATION: The HER2-enriched subtype can identify patients with HER2-positive breast cancer who are likely to benefit from dual HER2 blockade therapies. FUNDING: GlaxoSmithKline, Susan Komen Foundation, CERCA Programme-Generalitat de Catalunya, Banco Bilbao Vizcaya Argentaria Foundation, Pas a Pas, and the Breast Cancer Research Foundation.
引用
- Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017. PMID: 28238593. doi:10.1016/S1470-2045(17)30021-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。